No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Celltrion Denosumab Phase 3 Study Results
As reported in April this year, Celltrion presented the 78-week results of its Phase 3 study of CT-P41, biosimilar to Amgen’s Prolia® (denosumab), at the World Congress on Osteoporosis held in London from 11-14 April 2024. On 6 August 2024, Celltrion announced that...